Zenflow Announces $24 Million Financing Round to Fund FDA Filing & Commercial Preparation
Round to Support PMA Submission of Minimally Invasive Treatment for Enlarged Prostate Symptoms
SOUTH SAN FRANCISCO, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) — Zenflow, Inc., a medical device company developing a minimally invasive treatment for urinary obstruction caused by enlarged prostate, or benign prostatic hyperplasia (BPH), today announced that it has closed a $24 million Series C financing round. The round includes new investor Cook Medical as well as existing investors Invus Opportunities, F-Prime Capital, Medical Technology Venture Partners and others. Funds will be used to support the company’s Pre-Market Approval (PMA) submission and to prepare for commercialization upon FDA approval of its Spring® System, a minimally invasive treatment option for patients who suffer debilitating symptoms due to enlarged prostate.
